{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40","upperLimit":"100","value":"85"}]}],"title":"Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"100","value":"90"}]}],"title":"Day 70"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"the efficacy of the regimen as determined by engraftment rate and establishment of donor hematopoietic chimerism at day +28 and day +70.","dispersionType":"Full Range","groups":[{"description":"Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day","id":"OG000","title":"Cohort I"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"days +28 and +70","title":"Percent of Participants With Chimerism: Full Donor Chimerism Defined as >95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting","type":"PRIMARY","unitOfMeasure":"percent of participants"}